Elevated baseline IgE levels and comorbid type 2 conditions such as asthma or chronic rhinosinusitis with nasal polyps are indicative of systemic type 2 inflammation, for which dupilumab may be more effective due to its broader suppression of type 2 cytokine signaling through dual IL-4 and IL-13 blockade. The gene discussed is IL13; the disease is nasal cavity polyp.